THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q1 2019 13F Holders as of 31 Mar 2019

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
101.59%
Total 13F principal
$239,033,006
Principal change
+$10,728,745
Total reported market value
$244,473,552
Number of holders
24
Value change
+$9,256,895
Number of buys
10
Number of sells
14

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q1 2019

As of 31 Mar 2019, THERAVANCE INC - CORPORATE OBLIG was held by 24 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $239,033,006 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, Antara Capital LP, ADVENT CAPITAL MANAGEMENT /DE/, CNH PARTNERS LLC, CALAMOS ADVISORS LLC, LAZARD ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, SSI INVESTMENT MANAGEMENT INC, Man Group plc, and AMERIPRISE FINANCIAL INC. This page lists 24 institutional bondholders reporting positions for the Q1 2019 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.